ASCO 2018: Patients Receiving Everolimus for Advanced Breast Cancer Experience a Significant Increase in Gastrointestinal, Hepatic, and Hematologic Toxicities
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.